ctDNA models for predicting survival outcomes in mCRPC

Susan Halabi, PhD, FSCT, FASA, FASCO, Duke University Medical Center, Durham, NC, discusses a clinical-genetic (CG) circulating tumor (ctDNA)-based model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC). Whilst the model can aid clinicians on categorizing patients into disease aggressiveness and progression, the next step of the model is to become externally validated. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.